Otto C Boerman
Overview
Explore the profile of Otto C Boerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
319
Citations
7475
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
van Oostenbrugge T, Langenhuijsen J, Oosterwijk E, Boerman O, Jenniskens S, Oyen W, et al.
Eur J Nucl Med Mol Imaging
. 2019 Nov;
47(8):1864-1870.
PMID: 31768601
Purpose: Detection of residual or recurrent vital renal tumor on follow-up (FU) cross-sectional imaging after ablative therapy is challenging. The specific and high expression levels of carbonic anhydrase IX (CAIX)...
12.
Derks Y, Lowik D, Sedelaar J, Gotthardt M, Boerman O, Rijpkema M, et al.
Theranostics
. 2019 Oct;
9(23):6824-6839.
PMID: 31660071
Despite recent improvements in imaging and therapy, prostate cancer (PCa) still causes substantial morbidity and mortality. In surgical treatment, incomplete resection of PCa and understaging of possible undetected metastases may...
13.
Lobeek D, Bouwman F, Aarntzen E, Molkenboer-Kuenen J, Flucke U, Nguyen H, et al.
J Nucl Med
. 2019 Sep;
61(2):270-275.
PMID: 31519800
Arteriovenous malformations (AVMs) have an inherent capacity to form new blood vessels, resulting in excessive lesion growth, and this process is further triggered by the release of angiogenic factors. Ga-labeled...
14.
Elekonawo F, Lutje S, Franssen G, Bos D, Goldenberg D, Boerman O, et al.
EJNMMI Res
. 2019 Sep;
9(1):86.
PMID: 31485790
Background: Image-guided surgery may improve surgical outcome for colorectal cancer patients. Here, we evaluated the feasibility of a pretargeting strategy for multimodal imaging in colorectal cancer using an anti-carcinoembryonic antigen...
15.
Lutje S, Heskamp S, Franssen G, Frielink C, Kip A, Hekman M, et al.
Theranostics
. 2019 Jun;
9(10):2924-2938.
PMID: 31244933
Prostate cancer (PCa) recurrences after surgery frequently occur. To improve the outcome after surgical resection of the tumor, the theranostic multimodal anti-PSMA targeting agent In-DTPA-D2B-IRDye700DX was developed and characterized for...
16.
Verhoeff S, van Es S, Boon E, van Helden E, Angus L, Elias S, et al.
Eur J Nucl Med Mol Imaging
. 2019 Jun;
46(9):1931-1939.
PMID: 31172212
Purpose: The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced...
17.
Op t Veld R, Joosten L, van den Boomen O, Boerman O, Kouwer P, Middelkoop E, et al.
Biomater Sci
. 2019 May;
7(7):3041-3050.
PMID: 31115398
Wounds often result in scarring, prolonged morbidity, and loss of function. New interactive and modifiable hydrogel wound dressings are being developed for these injuries. Polyisocyanopeptide (PIC) gel is a promising...
18.
Lutje S, Franssen G, Herrmann K, Boerman O, Rijpkema M, Gotthardt M, et al.
J Nucl Med
. 2019 Jan;
60(7):1017-1022.
PMID: 30655329
The aim was to compare the prostate-specific membrane antigen (PSMA)-targeting characteristics of PSMA-11, radiolabeled on the basis of chelation of F-AlF, with those of Ga-PSMA-11 to image PSMA-expressing xenografts. Labeling...
19.
Huizing F, Hoeben B, Franssen G, Boerman O, Heskamp S, Bussink J
Mol Pharm
. 2018 Dec;
16(2):701-708.
PMID: 30550290
Tumor hypoxia plays a major role in radio- and chemotherapy resistance in solid tumors. Carbonic Anhydrase IX (CAIX) is an endogenous hypoxia-related protein, which is associated with poor patient outcome....
20.
Heskamp S, Wierstra P, Molkenboer-Kuenen J, Sandker G, Thordardottir S, Cany J, et al.
Cancer Immunol Res
. 2018 Nov;
7(1):150-161.
PMID: 30459153
Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive responses in subgroups of patients with cancer. PD-L1 expression in tumors seems to be...